MD Conference Express EASD 2012 - (Page 4)
Dear Colleagues:
The leadership of the American Diabetes Association (ADA), in partnership with The Goodwin Group International LLC, is pleased to present this special edition of MD Conference Express®. This publication presents peer-reviewed highlights from the 48th Annual European Association for the Study of Diabetes (EASD) Congress. The ADA and the EASD have worked together collaboratively for many years, and EASD’s annual meeting continues to provide a forum for the presentation and dissemination of important research in diabetes and its complications. The scope and quality of the abstracts presented continue to make the EASD Congress an exciting and innovative forum where advances in diabetes research can be translated into practical applications for the clinician. This year’s meeting included a robust discussion of the recent ADA/EASD position statement that focused on patient-centered care for the treatment of type 2 diabetes. Guidelines mirror the statement and stress patient preferences in the treatment process, an approach that takes into account patient attitudes, risks of therapy, disease duration, life expectancy, comorbidities, the presence of complications, and available resource and support systems. Important clinical trials presented at the EASD congress included DIA-AID 1, a global Phase 3 study which showed that DiaPep277 is safe and represents a promising therapeutic strategy in patients with newly diagnosed type 1 diabetes, an open-label extension of the DURATION-1study which showed long-term exenatide treatment to be associated with significant, sustained improvement in glycemic control as well as improvements in cardiometabolic measures, and the BEGIN®: EARLY study that compared basal insulin with a dipeptidyl peptidase-4 inhibitor as add-on therapy to oral antidiabetic agents in patients with uncontrolled type 2 diabetes. In addition to learning about the results of top late-breaking clinical trials in this dedicated highlights report, you will also find new information in selected, challenging areas of diabetes care including novel oral agents and possible links between type 1 diabetes and coronary artery disease. Other topics of clinical interest include the challenges of pharmaceutical management of diabetic peripheral neuropathy and the effect of screening for diabetes on long-term mortality rates. Whether you were able to attend the congress or not, we hope that you find this issue of MD Conference Express® and the access it provides to advances in diabetes care to be useful in your practice.
Vivian Fonseca, MD, FRCP President, Medicine and Science American Diabetes Association Professor of Medicine Tulane University School of Medicine Metairie, Louisiana, USA
Geralyn R. Spollett, MSN, ANP-BC, CDE President, Health Care and Education American Diabetes Association Yale University School of Medicine New Haven, Connecticut, USA
4
November 2012
www.mdconferencexpress.com
http://www.mdconferencexpress.com
Table of Contents for the Digital Edition of MD Conference Express EASD 2012
MD Conference Express EASD 2012
Contents
Understanding Incretin Hormone Action and the Treatment of Diabetes
New ADA/EASD Guidelines Focus on Patient-Centered Care
ORIGIN Trial: Insulin Glargine and n-3 Fatty Acids Fail to Reduce CV Events in Diabetic Patients
Exenatide Once Weekly Sustained Improvement in Glycemic Control with Weight Loss Through 4 Years
DiaPep277® Shows Promise as a Therapeutic Strategy for T1DM
Linagliptin Proves Safe and Effective as Add-on Therapy to Basal Insulin
12-Week Treatment with LY2409021 Significantly Lowers HbA1C and Is Well Tolerated in Patients with T2DM
Insulin Degludec Is Superior to Sitagliptin in Improving Glycemic Control in Uncontrolled Patients with Type 2 Diabetes on Oral Agents
Dapagliflozin Does Not Impact Renal Function in Patients with T2DM
Population-Based Screening for T2DM:The ADDITION-Cambridge Trial
The Challenges of Pharmaceutical Management of Painful Diabetic Peripheral Neuropathy
Enterovirus Infection
Novel Oral Agents
GLP-1
Genetics
Renal Denervation
Hypertension and Renal Function Are Risk Factors for CAD in T1DM
MD Conference Express EASD 2012
https://www.nxtbook.com/nxtbooks/md_conference_express/easd2012
https://www.nxtbookmedia.com